Skip to content
Biodatica
Start free

Ente Ospedaliero Ospedali Galliera

Genova, Italy

OncologymRNAPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms

4mo agoTrial registeredMar 11, 2026Source filing (opens the source filing in a new tab)

Momentum

70no change

Momentum 70 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

375 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Sep 22, 2022

    Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary · RECRUITING · sponsor: Ente Ospedaliero Ospedali Galliera · Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

    ClinicalTrials.gov · NCT05601700 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Mar 15, 2021

    Neoplasms, Cancer, Treatment-Related · COMPLETED · sponsor: Ente Ospedaliero Ospedali Galliera · BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

    ClinicalTrials.gov · NCT04932863 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jul 1, 1996

    Breast Cancer Invasive · COMPLETED · sponsor: Ente Ospedaliero Ospedali Galliera · Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms

    ClinicalTrials.gov · NCT06982313 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources